IMP — Vietnamese Stock News

Imexpharm (IMP) board members resign after Livzon Pharmaceutical Group acquires 67.87% stake. AGG and OCB also announce leadership changes.

Three IMP board members resign after Lian SGP Holding, a Livzon subsidiary, acquires 67.87% of Imexpharm for ~VND 6,000B (USD 240M).

Imexpharm (IMP) Chairman Woo Sungmin and two board members resign on May 18, 2026, following Chinese pharma Livzon's acquisition of 67.87% stake.

SK Group sells 61.8% of Imexpharm for ~$200M, doubling its investment. Livzon Pharmaceutical acquires 67.87% of IMP for VND 6,000B.

China's Livzon Pharmaceutical buys 67.87% of Imexpharm (IMP) from SK Group for ~VND 6,000B. IMP reports 2025 revenue up 16%, pre-tax profit up 10.4%.

Livzon Pharmaceutical Group acquires 67.87% of Imexpharm (IMP) for ~VND 6,000B. Deal highlights foreign control trend in Vietnam's pharma sector.

Imexpharm (IMP) leaders sell shares after Livzon Group acquires 67.87% stake for ~$240M. Deal shifts control from SK Group to Chinese pharma giant.

Imexpharm (IMP) leaders sold shares on May 7 as Lian SGP Holding bought a 67.87% stake from SK Group for nearly VND 6,000B, becoming the new parent company.

Chinese pharma Livzon buys 67.87% of Imexpharm (IMP) for VND 6,000B ($240M), gaining control of Vietnam's top antibiotic maker.

Livzon subsidiary Lian SGP buys 67.87% of Imexpharm (IMP) for ~VND 6,000B ($240M), becoming the parent company of the leading Vietnamese pharma firm.

Livzon unit Lian SGP buys 67.87% of Imexpharm (IMP) at VND 57,400/share, becoming majority holder. SK Group entities and IMP leaders register to sell shares.

Chinese pharma giant Livzon acquires 67.87% of Imexpharm (IMP) via tender offer at VND 57,400/share, totaling ~VND 6,000 billion (USD 240 million).

Imexpharm (IMP) CEO and two Deputy CEOs register to sell 607,400 shares from mid-April to mid-May 2026, citing personal financial reasons. The HoSE-listed pharmaceutical firm targets record 2026 revenue of VND 3,200B.